

KEPUSTAKAAN

- Aleem, E. & Arceci, R. J. 2015. Targetting cell cycle regulators in hematologic malignancies. *Front Cell Dev Biol*, 3(16):1-22.
- Alejandro, F., Rangel, L. & Chavez-Valencia, V. 2017. FLT3-ITD and its current role in acute myeloid leukemia. *Med Oncol*, 34:114-27.
- Allahyari, A., Sadeghi, M., Ayatollahi, H., Yazdi, H. N. & Tavakol, M. 2016. Frequency of FLT3 (ITD, D835) gene mutations in acute myelogenous leukemia : a report from Northeastern Iran. *Asian Pac J Cancer Prev*, 17(9):4319 - 22.
- Almeida, A. M. & Ramos, F. 2016. Acute myeloid leukemia in the older adults. *Leuk Res Rep*, 6:1-7.
- Anglada, M. P. & Torras, S. P. 2015. Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. *Front Pharmacol*, 6(13):1-14.
- Annesley, C. E. & Brown, P. 2014. The biology and tergetting of FLT3 in pediatric leukemia. *Front Oncol*, 4(263):1-18.
- Aref, S., Mabed, M., El-Sherbiny, M., Selim, T. & Metwaly, A. 2006. Cyclin D1 expression in acute leukemia. *Hematology*, 11(1):31-34.
- Au, W. Y., Fung, A., Chim, C. S., Lie, A. K., Liang, R., Ma, E. S., Chan, C. H., Wong, K. F. & Kwong, Y. L. 2004. FLT3 abberation in acute promyelocytic leukemia: clinicopathological associations and prognostic impact. *Br J Haematol*, 125:463-9.
- Bacher, U., Haferlach, C., Kern, W., Haferlach, T. & Schnittger, S. 2008. Prognostic relevance of FLT3-TKD mutations in AML : the combination matters-an analysis of 3082 patients. *Blood*, 111(5):2527-39.
- Bagrintseva, K., Geisenhof, S., Kern, R., Eichenlaub, S., Reindl, C., Ellwart, J. W., Hiddemann, W. & Spiekermann, K. 2005. FLT-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). *Blood*, 105(9):3679-88.
- Bao, L., Wang, X., Ryder, J., Ji, M., Chen, Y., Chen, H., Sun, H., Yang, Y., Du, X., Kerzic, P., Gross, S. A., Yao, L., Lv, L., Fu, H., Lin, H. & Irons, R. D. 2006. Prospective study of 174 de novo acute myelogenous leukemia according to

the WHO classification: subtypes, cytogenetic features and FLT3 mutations. *Eur J Haematol*, 77:35-45.

- Bellis, E. D., Fianchi, L., Buccisano, F., Criscuolo, M., Maurillo, L., Cicconi, L., Brescini, M., Principe, M. I. D., Veroli, A. D., Venditti, A., Amadori, S., Arcese, W., Lo-Coco, F. & Voso, M. T. 2017. Treatment of low blast count AML using hypomethylating agents. *Mediterr J Hematol Infect Dis*, 9(1):1-7.
- Boddu, P., Kantarjian, H., Borthakur, G., Kadia, T., Daver, N., Pierce, S., Andreeff, M., Ravandi, F., Cortes, J. & Kornblau, S. M. 2017. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. *Blood advances*, 1(19):1546-51.
- Brucher, B. L. & Jamall, I. S. 2016. Somatic mutation theory - why it's wrong for most cancers. *Cell Physiol Biochem*, 38:1663-80.
- Burnatt, G., Licinio, M. A., Gaspar, P. C., Ferreira, A. S., Reis, M. L., Moraes, A. C. R. D., Sincero, T. C. M. & Silva, M. C. S. 2017. Anaysis of the presence of FLT3 gene mutation abd association with prognostic factors in adult and pediatric acute leukemia patients. *Braz. J. Pharm*, 53(2):1-11.
- Calo, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M., Gebbia, N. & Russo, A. 2003. STAT proteins: from normal control of cellular events to tumorigenesis. *J Cell Physiol*, 197:157-68.
- Catala, A., Pastor-Anglada, M., Caiedes-Cardenas, L., Malatesta, R., Rives, S., Vega-Garcia, N., Camos, M. & Fernandez-Calotti, P. 2016. FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. *Oncotarget*, 7(31):49786-99.
- Chabner, B. A. 2008. Antimetabolites: fluoropyrimidines and other agents. In: CHABNER, B. A., LYNCH, T. J. & LONGO, D. L. (eds.) *Harrison's Manual of Oncology*. United States of America: McGraw-Hill Companies Inc.
- Cheng, Y., Wang, Y., Wang, H., Chen, Z., Lou, J., Xu, H., Wang, H., Qian, W., Meng, H. & Jin, J. 2009. Cytogenetic profile of de novo acute myeloid leukemia : a study based on 1432 patients in a single institution of China. *Leukemia*, 23:1801-6.
- Dalal, B. I., Mansoor, S., Manna, M., Pi, S., Sauro, G. D. & Hogge, D. E. 2012. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. *Clin Lymph Myeloma Leuk*, 12(4):274-9.

- Dang, H., Chen, Y., Kamel-Reid, S., Brandwein, J. & Chang, H. 2013. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. *J.humpath*, 44:2038-46.
- Dao, M. A., Hannum, C. H., Kohn, D. B. & Nolte, J. A. 1997. FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long term hematopoiesis in immune deficient mice after ex vivo retroviral mediated transduction. *Blood*, 89(2):446-56.
- Ebrahim, E. K., Assem, M. M., Amin, A. I., Kamel, M. M., Meligui, Y. M. E. & Metwally, A. M. 2016. FLT3 internal tandem duplication mutation, cMPL, and CD34 expressions predict low survival in acute myeloid leukemia patients. *Ann clin lab sci*, 46(6):592-601.
- Elakkad, M. A., Abdelhalim, A. F., Salah, H. E. & Amer, A. Y. 2019. CD34 expression and FLT3 mutation are independent poor prognostic factors in normal karyotype acute myeloid leukemia *Egypt J Haematol*, 44:48-53.
- Eltzshig, H. K., Abdulla, P., Hoffman, E., Hamilton, K. E., Daniels, D., Schonfeld, C., Loffler, M., Reyes, G., Duszenko, M., Karhausen, J., Robinson, A., Westerman, K. A., Coe, I. R. & Colgan, S. P. 2005. HIF-1 dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. *J Exp Med*, 202(11):1493-505.
- Elyamany, G., Awad, M., Alsuhaibani, O., Fadalla, K., Sharif, O. A., Shahrani, M. A., Alabbas, F. & Al-Abulaaly, A. 2014a. FLT3 internal tandem duplication and D835 mutation in patients with acute lymphoblastic leukemia and its clinical significance. *Mediterr J Hematol Infect Dis*, 6(1):e2014038.
- Elyamany, G., Awad, M., Fadalla, K., Albalawi, M., Shahrani, M. A. & Abdulaaly, A. A. 2014b. Frequency and prognostic relevance of FLT3 mutations in Saudi acute myeloid leukemia patients. *Adv Hematol*, 2014:1-7.
- Fernandes, J. C., Alves, A. P. N. R., Silva, J. L. C., Scopim-Ribeiro, R., Fenerich, B. A., Simoes, B. P., Rego, E. M., Neto, J. a. M. & Traina, F. 2018. Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival. *App Cancer Res*, 38(7):1-4.
- Gari, M., Abuzenadah, A., Chaudhary, A., Al-Qahtani, M., Banni, H., Ahmad, W., Al-Sayes, F., Lary, S. & Damanhour, G. 2008. Detection of FLT3 Oncogene Mutations in Acute Myeloid Leukemia Using Confirmation Sensitive Gel Electrophoresis. *Int. J. Mol. Sci*, 9:2194-204.

- Gorczyca, W. & Emmons, F. 2008. Differential diagnosis - phenotype. *Atlas of Differential Diagnosis in Neoplastic Hematopathology*. 2nd ed ed. New York, USA: Informa Healthcare.
- Grafone, T., Palmisano, M., Nicci, C. & Storti, S. 2012. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia : biology and treatment. *Oncol Rev*, 6(1):64-74.
- Habib, A., Johargy, A., Mahmood, K. & Humma 2014. Design and determination of the sample size in medical research. *IOSR-JDMS*, 13(5):21-31.
- Heffner, L. T. 2007. Acute myeloid leukemia : epidemiology, risk factors, and classification. In: SEKERES, M. A., KALAYCIO, M. R. & BOLWELL, B. J. (eds.) *Clinical malignant hematology*. 1st ed. United states of america: The McGraw-Hill.
- Hikari, S. A., Gatot, D. & Endang, W. 2012. Hasil pengobatan leukemia mieloblastik akut pada anak. *Sari Pediatri*, 14(1):40-46.
- Huang, W., Zeng, X., Shi, Y. & Liu, M. 2017. Functional characterization of human equilibrative nucleoside transporter 1. *Protein Cell*, 8(4):284-295.
- Iarc. 2018. *GLOBOCAN 2018: estimated cancer incidence, mortality, and prevalence worldwide in 2018* [Online]. France: World Health Organization. Available: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx [Accessed April 26th 2019 2019].
- Jatav, J., Niranjana, A. K. & Jain, B. 2016. Clinicopathological study of acute leukemia - a multiparameter study. *Ijcmr*, 3(11):3117-21.
- Jin, G., Matsushita, H., Asai, S., Tsukamoto, H., Ono, R., Nosaka, T., Yahata, T., Takahashi, S. & Miyachi, H. 2009. FLT3-ITD induces Ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. *Biochem.Biophys.Res.Commun*, 390:1001-6.
- Kasper, S., Breitenbuecher, F., Heidel, F., Hoffarth, S., Markova, B., Schuler, M. & Fischer, T. 2012. Targeting MCL-1 sensitizes FLT3-ITD positive leukemias to cytotoxic therapy. *Blood Cancer J*, 2(3):1-11.
- Kennedy, J. & Barabe, F. 2008. Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia. *Leukemia*, 22:2029-40.
- Kim, J. K. & Diehl, J. A. 2009. Nuclear cyclin D1: an oncogenic driver in human cancer. *J Cell Physiol*, 220(2):292-6.

- Kim, K. I., Huh, I. S., Kim, I. W., Park, T., Ahn, K. S., Yoon, S. S., Yoon, J. H. & Oh, J. M. 2013. Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients. *Eur J Cancer*, 49:403-10.
- Kiyoi, H., Naoe, T., Yokota, S., Nakao, M., Minami, S., Kuriyama, K., Takeshita, A., Saito, K., Hasegawa, S., Shimodaira, S., Tamura, J., Shimazaki, C., Matsue, K., Kobayashi, H., Arima, N., Suzuki, R., Morishita, H., Saito, H., Ueda, R. & Ohno, R. 1997. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. *Leukemia*, 11:1447-52.
- Koh, Y., Park, J., Ahn, K. S., Kim, I., Bang, S. M., Lee, J. H., Yoon, S. S., Lee, D. S., Lee, Y. Y., Park, S. & Kim, B. K. 2009. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathwat. *Ann Hematol*, 88:1089-97.
- Kosasih, A. S., Setiawan, L., Hartini, S., Kresno, S. B. & Indarini 2011. Immunophenotyping in the diagnosis and classification of acute leukemia: " Dharmais" Cancer Hospital experience. *Indonesian J Canc*, 5(1):3-8.
- Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A., Walker, H., Wheatley, K., Bowen, D. T., Burnett, A. K., Glodstone, A. H. & Linch, D. C. 2001. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. *Blood*, 98(6):1752-61.
- Krause, J. R. 2000. Morphology and classification of acute myeloid leukemia. *Clin Lab Med*, 20(1):1-16.
- Kumsaen, P., Fucharoen, G., Sirijerachai, C., Chainansamit, S.-O., Wisanuyothin, N., Kuwatjanakul, P. & Wiangnon, S. 2016. FLT3-ITD Mutations in Acute Myeloid Leukemia Patients in Northeast Thailand. *Asian Pac J Cancer Prev*, 17(9):4395-99.
- Lafage, M. & Viguie, F. 2017. Leukemia section : M3/M3v acute myeloid leukemia (AML M3/M3v). *Atlas Genet Cytogenet Oncol Haematol*, 22(4):148-53.
- Lamba, J. K. 2009. Genetic factors influencing cytarabine therapy. *Pharmacogenomics*, 10(10):1657-74.
- Li, H., Wang, Y. & Lou, F. 1999. Expression of cyclin D1 mRNA in acute leukemia patients and its clinical implication. *Zhonghua Xueyexue Zashi*, 20(7):357-8.

- Licinio, M. A. & Silva, M. C. S. D. 2010. Importance of detecting FLT3 and NPM1 gene mutations in acute myeloid leukemia - World Health Organization classification 2008. *Rev Bras Hematol Hemoter*, 32(6):476-81.
- Liersch, R., Tidow, C. M.-., Berdel, W. E. & Krug, U. 2014. Prognostic factors for acute myeloid leukemia in adults- biological significance and clinical use. *BJH*, 165:17-38.
- Loken, M. R., Loosdrecht, A. V. D., Ogata, K., Orfao, A. & Wells, D. A. 2008. Flow cytometry in myelodysplastic syndromes: report from a working conference. *J.leukres*, 32:5-17.
- Mahmood, H., Abdullah, W. Z., Yong, A. C., Ahmed, S. A., Abdullah, A. D., Baba, A. A., Ankathil, R., Husin, A., Hussein, A. R., Mustaffa, R. & Hassan, R. 2014. A review of AML classification: a single institution experience in a developing country. *J Hematop*, 7:3-8.
- Mead, A. J. 2009. *The clinical and biological consequences of different FLT3 mutations in patients with AML*. Doctor of Philosophy, University College London.
- Mehta, S. V., Shukla, S. N. & Vora, H. H. 2012. Comprehensive FLT3 analysis in indian acute myeloid leukemia. *J. Blood Lymph*, 2(1):1-13.
- Meir, W., Byrd, J. C. & Bloomfield, C. D. 2010. Acute and chronic myeloid leukemia. In: LONGO, D. L. (ed.) *Harrison's Hematology and Oncology*. 1st ed. New York: The McGraw Hill Companies.
- Mills, K. I., Gilkes, A. F., Walsh, V., Sweeney, M. & Gale, R. 2005. Rapid and sensitive detection of internal tandem duplication and activating loop mutations of FLT3. *Br J Haematol*, 130:203-8.
- Molica, M. & Breccia, M. 2015. FLT3-ITD in acute promyelocytic leukemia: clinical distinct profile but still controversial prognosis. *J.leukres*, 39(4):397-9.
- Musgrove, E. A., Caldon, C. E., Barclough, J., Stone, A. & Sutherland, R. L. 2011. Cyclin D as a therapeutic target in cancer. *Nat. Rev.Cancer*, 11:558-72.
- Nci. 2019. *Cancer stat facts : leukemia - acute myeloid leukemia (AML)* [Online]. National Cancer Institute. Available: <http://seer.cancer.gov/statfacts/html/amyl.html> [Accessed February 26th 2020 2020].
- Notopuro, P. B., Hajat, A., Sedana, M. P., Boediwarsono & Bintoro, U. Y. 2018. Data epidemiologi penderita keganasan hematologi dewasa berdasarkan hasil

pemeriksaan sumsum tulang tahun 2014 - 2016 di Surabaya. Fakultas Kedokteran Universitas Airlangga.

- Notopuro, P. B., Notopuro, H., Budiwijono, I. & Adhipireno, P. 2017. The difference in initial leukocyte count, bone marrow blast cell count, and CD34 expression in patients with acute myeloid leukemia with and without NPM1 gene mutation. *IJBC*, 9(2):2-5.
- O'brien, E. C., Prideaux, S. & Chevassut, T. 2014. The epigenetic landscape of acute myeloid leukemia. *Adv Hematol*, 2014:1-15.
- Owen, C. J. & Fitzgibbon, J. 2010. The genetics of acute myeloid leukemia. In: PROVAN, D. & GRIBBEN, J. G. (eds.) *Molecular Hematology*. United Kingdom: Blackwell Publishing Ltd.
- Pallis, M., Zhu, Y.-M. & Russell, N. 1997. BCL-XL is heterogeneously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. *Leukemia*, 11:945-49.
- Pawar, R., Bali, O. P. S., Malhotra, B. K. & Lamba, G. 2014. Recent advances and novel agents for FLT3 mutated acute myeloid leukemia. *Stem Cell Investig*, 1(7):300-6.
- Peschel, I., Podmirseg, S. R., Taschler, M., Duyster, J., Gotze, K. S., Sill, H., Nachbaur, D., Jakel, H. & Hengst, L. 2017. FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27 Kip1 in acute myeloid leukemia. *Haematologica*, 102(8):1378-90.
- Picharski, G. L., Andrade, D. P., Fabro, A. L. M., Lenzi, L., Tonin, F. S., Ribeiro, R. C. & Figueiredo, B. C. 2019. The impact of FLT3 gene mutations in acute promyelocytic leukemia : a meta-analysis. *Cancer*, 11:1311-25.
- Qie, S. & Diehl, A. 2016. Cyclin D1, cancer progression , and opportunities in cancer treatment. *J. Mol. Med*, 94(12):1313-26.
- Rezael, N., Arandi, N., Valibeigi, B., Haghpanah, S., Khansalar, M. & Ramzi, M. 2017. FMS-Like tyrosine kinase 3 (FLT3) and nucleophosmin 1 (NPM1) in Iranian adult acute myeloid leukemia patients with normal karyotypes : mutation status and clinical and laboratory characteristics. *Turk J Hematol*, 34:300-6.
- Rombouts, E. 2004. *Internal tandem duplications in the Flt3-gene in human acute myeloid leukemia*. Erasmus Medical Center.

- Rooij, J. D. E. D., Zwaan, C. M. & Eibrink, M. V. D. H. 2015. Pediatric AML: from biology to clinical management. *J.Clin.Med*, 4:127-49.
- Sampath, D., Mali, R., Lasater, E. A., Doyle, K., Malla, R., Boghaert, E. R., Souers, A. & Levenson, J. D. 2017. FLT3 inhibition overcomes resistance to the Bcl-2 selective antagonist, venetoclax, in FLT3-ITD mutant AML models. *22nd EHA congress*. Madrid: European Hematology Association.
- Sarojam, S., Vijay, S., Raveendran, S., Sreedharan, J., Narayanan, G. & Sreedharan, H. 2014. FLT3 Mutation as a Significant Prognostic Marker in de novo Acute Myeloid Leukemia Patients: Incidence, Distribution and Association with Cytogenetic Findings in a Study from South India. *MEJC*, 5(4):185-96.
- Schnittger, S., Schoxh, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Loffler, H., Sauerland, C. M., Serve, H., Buchner, T., Haferlach, T. & Hiddemann, W. 2002. Analysis of FLT3 length mutation in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. *Blood*, 100(1):59-67.
- Schuurhuis, G. J., Kedler, A., Terwijn, M., Rutten, A. P., Smit, L., Zweegman, S. & Ossenkoppele, G. 2010. The prognostic value of CD34 expression in acute myeloid leukemia. A mystery solved. *Blood*, 116:2725.
- Seif, A. E. 2011. Pediatric leukemia predisposition syndrome: clues to understanding leukemogenesis. *Canc. Gen*, 204:227-44.
- Supriyadi, E., Purwanto, I. & Widjajanto, P. H. 2013. Terapi leukemia mieloblastik akut anak: protokol ara-c, doxorubicine, dan etoposide (ADE) vs modifikasi Nordic society of pediatric hematology and oncology (m-NOPHO). *Sari Pediatri*, 14(6):345-50.
- Sutherland, J. V. & Bailar, J. C. 1984. The multihit model of carcinogenesis: etiologic implications for colon cancer. *J Chron Dis*, 37(6):465-80.
- Suzuki, R., Takemura, K., Tsutsumi, M., Nakamura, S., Hamajima, N. & Seto, M. 2001. Detection of cyclin D1 overexpression by real-time reverse transcriptase-mediated quantitative polymerase chain reaction for diagnosis of mantle cell lymphoma. *AM J Path*, 159(2):425-30.
- Takahashi, S. 2011a. Current findings for recurring mutations in acute myeloid leukemia. *J. Hematol. Oncol*, 4(36):1-11.

- Takahashi, S. 2011b. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia : biology and therapeutic implications. *J. Hematol. Oncol*, 4(13):1-10.
- Tefferi, A. & Letendre, L. 2012. Going beyond 7+3 regimens in the treatment of adult acute myeloid leukemia. *J Clin Oncol* 30(20):2425-8.
- Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. & Lilmer, T. 2002. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia : association with FAB subtypes and identification of subgroups with poor prognosis. *Blood* 99:4326-35.
- Uras, I. Z., Belluti, F. & Sexl, V. 2017. p27 in FLT3 driven acute myeloid leukemia : many roads lead to ruin. *Haematologica*, 102(8):1299-302.
- Vannucchi, A. M., Pieri, L. & Guglielmelli, P. 2011. JAK2 allele burden in the myeloproliferative neoplasmas: effects on phenotype, prognosis, and change with treatment. *Ther Adv Hematol*, 2(1):21-32.
- Wan, H., Zhu, J., Chen, F., Huang, H., Han, X., Zhong, L., Zhong, H., Xu, L., Ni, B. & Zhong, J. 2014. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. *J Exp Clin Cancer Res*, 33(90):1-10.
- Wang, L., Xu, W. L., Meng, H. T., Qian, W. B., Mai, W. Y., Tong, H. Y., Mao, L. P., Tong, Y., Qian, J. J., Lou, Y. J., Chen, Z. M., Wang, Y. G. & Jin, J. 2010a. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics. *J Zhejiang Univ-Sci B (Biomed & Biotechnol)*, 11(10):762-70.
- Wang, W., Wang, X.-Q., Xu, X.-P. & Lin, G.-W. 2010b. Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukemia: analysis of patients from the shanghai leukemia co-operative group. *J Int Med Res*, 38:432-42.
- Wang, Y. X., Zhang, J. H. & Gu, Z. W. 2009. Beta catenin and cyclin D1 mRNA levels in newly diagnosed patients with acute myeloid leukemia and their significance. *Zhongguo Shi Yang Xue Ye Xue Za Zhi*, 17(2):304-8.
- Widiaskara, I. M., Permono, B., Ugrasena, I. & Ratwita, M. 2010. Luaran pengobatan fase induksi pasien leukemia limfoblastik akut pada anak di rumah sakit umum dr. soetomo surabaya. *Sari Pediatri*, 12(2):128-34.

- Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimazaki, C., Akiyama, H., Saito, K., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Saito, H., Ueda, R., Ohno, R. & Naoe, T. 2001. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. *Blood*, 97(8):2434-40.
- Yang, L., Liu, X., I, Q., Zhu, X., Wang, B. & Zhu, W. 2014. Immunophenotyping characteristics of AML and their correlation with the curative effects. *Zhongguo Shi Yang Xue Ye Xue Za Zhi*, 22(1):1-5.
- Yohe, S. 2015. Molecular genetic markers in acute myeloid leukemia. *J. Clin. Med*, 4:460-78.
- Yunus, N. M., Johan, M. F., Al-Jamal, H. a. N., Husin, A., Hussein, A. R. & Hassan, R. 2015. Characterization and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukemia Patients in Kelantan, Northeast Peninsular Malaysia. *Asian Pac J Cancer Prev*, 16(12):4869-72.
- Zhang, J., Visser, F., King, K. M., Baldwin, S. A., Young, J. D. & Cass, C. E. 2007. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. *Cancer Metast Rev*, 26:85-110.
- Zheng, R., Friedman, A. D. & Small, D. 2002. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3-ITD mutations. *Blood*, 100(12):4154-62.
- Zhu, H. H., Liu, Y.-R., Jiang, H., Lu, J., Qin, Y.-Z., Jiang, Q., Bao, L., Ruan, G. R., Jiang, B. & Huang, X. 2013. CD34 expression on bone marrow blast is a novel predictor of poor prognosis independent of FLT3-ITD in acute myeloid leukemia with NPM1 mutation. *J.leukres*, 37(6):624-30.
- Zidan, M., Shaaban, H. & Ghannam, D. E. 2013. Prognostic impact of nucleophosmin 1 (NPM1) gene mutations in Egyptian acute myeloid leukemia patients. *Turk J Hematol*, (30):129-36.